Blog

  • Wall Breaking? Bitcoin Faces Key Test Near $126K Trendline

    Wall Breaking? Bitcoin Faces Key Test Near $126K Trendline


    Bitcoin trades near $121.6K, testing major resistance at $126K. Analysts watch for a breakout or correction as futures open interest stays high.

    Bitcoin is trading near $121,600 after reaching a new all-time high above $126,000 earlier this week. The asset has slowed and is now moving sideways just below a major diagonal resistance that has capped the price for several months. Analysts are watching to see whether Bitcoin can break through or if it will be rejected once again.

    Meanwhile, the market is holding near a key level while open interest remains high in the futures market.

    Bitcoin Struggles Near Long-Term Resistance

    Bitcoin is facing resistance at a trendline that has held firm since earlier cycle tops. The latest weekly candle shows another rejection near $126,000, followed by a pullback of around 5.5%. Earlier this year, similar rejections led to drops of nearly 10% and close to 30%.

    The difference this time is the size of the pullbacks. Each rejection has been smaller than the last. Rekt Capital pointed out that “this trendline looks to be a weakening point of rejection,” suggesting sellers may be losing strength at this level.

    Source: Rekt Capital/X

    On the lower timeframes, Bitcoin is holding just above $121,000. This zone is marked by a previous support level and lines up with a Fibonacci retracement near $119,550. Daan Crypto Trades noted that this is the area to watch.

    The asset is currently consolidating in a tight range. Volume has slowed, which often happens before a larger move. The trend remains bullish overall. A confirmed higher low would support another leg higher, especially if resistance breaks.

    You may also like:

    Bearish Scenario Still in Play

    While short-term sentiment remains positive, some market participants are still cautious. Analyst Ali Martinez shared a scenario where Bitcoin gets rejected at $124,000 and begins a correction toward $96,000. If that level fails, the next major support is around $70,000.

    Bitcoin price chart
    Source: Ali Martinez/X

    The projected path shows a slow recovery beginning in late 2026, with Bitcoin climbing back toward $90,000. This scenario reflects a broader retracement, not a trend reversal, and suggests long-term structure could still remain intact.

    Futures Market Remains Heated

    Data from Glassnode shows that futures open interest is still elevated. This means that many traders are positioned on both the long and short sides. Sharp moves in either direction have triggered liquidations. Glassnode said the market is undergoing “a leverage reset” as volatility flushes out excess positions.

    With Bitcoin sitting just below resistance and leverage still high, traders are watching closely. A move above the current range could open the way toward $130,000. If resistance holds, another pullback could extend the current consolidation.

    SPECIAL OFFER (Sponsored)

    Binance Free $600 (CryptoPotato Exclusive): Use this link to register a new account and receive $600 exclusive welcome offer on Binance (full details).

    LIMITED OFFER for CryptoPotato readers at Bybit: Use this link to register and open a $500 FREE position on any coin!


    Continue Reading

  • AstraZeneca announces historic agreement with US Government to lower the cost of medicines for American patients

    AstraZeneca today announces a historic agreement with President Donald J. Trump’s administration to lower the cost of prescription medicines for American patients while preserving America’s cutting-edge biopharmaceutical innovation.

    At a landmark event at the White House, AstraZeneca CEO Pascal Soriot joined President Trump and members of his Administration to confirm the Company voluntarily met all requests set out in the President’s 31 July letter. The Company agrees to a range of measures which will enable American patients to access medicines at prices that are equalized with those available in wealthy countries.

    As part of the agreement, AstraZeneca will provide Direct-to-Consumer (DTC) sales to eligible patients with prescriptions for chronic diseases at a discount of up to 80% off list prices. AstraZeneca will participate in the TrumpRx.gov direct purchasing platform, which will allow patients to purchase medicines at a reduced cash price from AstraZeneca.

    AstraZeneca has also reached an agreement with the US Department of Commerce to delay Section 232 tariffs for three years, enabling the Company to fully onshore medicines manufacturing so that all of its medicines sold in America are made in America. This will be achieved through the Company’s recently announced $50 billion investment in US medicines manufacturing and R&D over the next five years to help deliver $80 billion in Total Revenue by 2030, 50% of which is expected to be generated in the US.

    Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Every year AstraZeneca treats millions of Americans living with cancer and chronic diseases and, as a result of today’s agreement, many patients will access life-changing medicines at lower prices. This new approach also helps safeguard America’s pioneering role as a global powerhouse in innovation and developing the next generation of medicines. It is now essential other wealthy countries step up their contribution to fund innovation.”

    AstraZeneca’s commitment to the US and American patients is further reflected in the Company’s largest single investment in a manufacturing facility to date, where the Company broke ground yesterday in Virginia. This facility will support AstraZeneca’s weight management and metabolic portfolio and our leading antibody drug conjugate cancer pipeline. Additionally, a newly expanded manufacturing facility in Coppell, Texas, will officially open next week. Looking ahead, AstraZeneca will open a cell therapy manufacturing facility in Rockville, Maryland early next year and its second major R&D centre in Cambridge, Massachusetts will open in late 2026.

    The US is AstraZeneca’s largest market by sales and is also home to 19 R&D, manufacturing and commercial sites. The Company’s US workforce exceeds more than 25,000 people and supports more than 100,000 jobs overall across the country. In 2025, AstraZeneca created approximately $20 billion of overall value to the American economy.

    Notes

    AstraZeneca’s agreement with US Government
    This is the second agreement that a pharmaceutical company has made with the US Department of Health and Human Services to lower the cost of medicines for American patients in the past two weeks. Specific terms of this agreement remain confidential.

    AstraZeneca
    AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca. The contents of AstraZeneca’s website do not form part of this document and no one should rely on such websites or the contents thereof in reading this document.

    Contacts
    For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

    Continue Reading

  • Sarepta to seek approval for gene therapy in rare muscular dystrophy

    Sarepta to seek approval for gene therapy in rare muscular dystrophy

    An experimental gene therapy from Sarepta Therapeutics increased levels of the gene missing in an ultra-rare form of muscular dystrophy, according to data the company presented Friday.

    The company has said it plans to file for approval in the disease, known as limb-girdle muscular dystrophy (LGMD) 2E. That would make it the first approved treatment in LGMD, a broad collection of highly rare diseases that can deprive patients of the ability to walk and in some cases shorten life. But it is likely to face a significant uphill battle. 

    The LGMD 2E therapy relies on the same gene-ferrying virus that Sarepta uses in its other treatments, including its approved gene therapy for Duchenne muscular dystrophy, Elevidys, and experimental gene therapies for several other LGMD subtypes. 

    STAT+ Exclusive Story

    This article is exclusive to STAT+ subscribers

    Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

    Continue Reading

  • Conservation Is the Work of Art: How The Lightning Field Made Land Art into Land Management

    Conservation Is the Work of Art: How The Lightning Field Made Land Art into Land Management

    Maya Livio

    Southwest of Black Mesa and north of Cerro Verde, Cibola County, New Mexico, 2015. License: CC0.